EUVIMEDEUVIMED entdecken
Klinische StudieMultizentrische StudieOpen Access · CC BY-NC 4.0

Effect of administration and withdrawal of the sodium‐glucose cotransporter 2 inhibitor, tofogliflozin, on renal protection in individuals with type 2 diabetes mellitus and diabetic nephropathy: A multicenter, single‐arm study ( RESTORE ‐nephropathy study)

Ayako Shigeta, Masami Tanaka iD, Shu Meguro iD, Jiro Morimoto, Takatoshi Imai, Akira Yamauchi, Yasuhiko Kanazawa, Toshihide Kawai, Koichiro Azuma, Satoru Yamada, Sho Endo, Hiroshi Itoh und 1 weitere

Journal of Diabetes Investigation · 2025

DOI: 10.1111/jdi.70018 ↗

Kurz gefasst

Klinische Studie in der Zeitschrift Journal of Diabetes Investigation, 2025. Verfasst von Ayako Shigeta und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan. Hauptthemen laut MEDLINE: Benzhydryl Compounds, Diabetes Mellitus, Type 2, Diabetic Nephropathies, Glucosides. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Kowa Company.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims/Introduction The mechanisms of the renoprotective effects of sodium‐glucose cotransporter 2 inhibitors are unknown. This study aimed to explore the effect and mechanism of tofogliflozin on urinary albumin by administration, withdrawal, and re‐administration. Materials and Methods Individuals with type 2 diabetes mellitus and stage 2 or 3 diabetic nephropathy were enrolled. Tofogliflozin was administered for 24 weeks, withdrawn for 12 weeks (withdrawal period), and re‐administered for 24 weeks. The primary endpoint was the change in urinary albumin/creatinine ratio (UACR). The secondary endpoints included hemoglobin A1c (HbA1c), hepatic biomarkers, lipid profiles, physical examinations, and blood counts.

Results

A total of 47 individuals were enrolled. UACR significantly decreased throughout the observation period. It also significantly decreased, increased, and again decreased during the period of the 1st administration, withdrawal, and re‐administration, respectively. HbA1c, body weight, waist circumference, and systolic blood pressure also showed the same tendency. Aspartate aminotransferase and alanine aminotransferase significantly decreased throughout the observation period, but did not increase during the withdrawal period.

Conclusions

Urinary albumin improved during the administration of tofogliflozin and worsened during its withdrawal, suggesting the reversibility of its renoprotective effect. The administration of tofogliflozin should be continued to avoid the reversal of glycemic control, renoprotective effects, and other beneficial effects.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Benzhydryl CompoundsDiabetes Mellitus, Type 2Diabetic NephropathiesGlucosidesSodium-Glucose Transporter 2 InhibitorsAgedFemaleHumansMaleMiddle AgedAlbuminuriaBiomarkersBlood GlucoseFollow-Up StudiesGlycated HemoglobinPrognosis

Stichwörter der Autor:innen

Diabetic nephropathyDrug withdrawalRenal protectionTofogliflozinUrinary albumin

Substanzen

6-((4-ethylphenyl)methyl)-3',4',5',6'-tetrahydro-6'-(hydroxymethyl)spiro(isobenzofuran-1(3H),2'-(2H)pyran)-3',4',5'-tri…Benzhydryl CompoundsBiomarkersBlood GlucoseGlucosidesGlycated Hemoglobinhemoglobin A1c protein, humanSodium-Glucose Transporter 2 Inhibitors

Autor:innen und Institutionen

  • Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.
  • Department of Medicine, Adachi Medical Center, Tokyo Women's Medical University School of Medicine, Tokyo, Japan.
  • Department of Endocrinology and Diabetes, JCHO Saitama Medical Center, Saitama, Japan.
  • Department of Diabetes and Rheumatology, Yokohama Municipal Citizen's Hospital, Yokohama, Japan.
  • Suruga Clinic, Shizuoka, Japan.
  • Department of Diabetes and Endocrinology, Kawasaki Municipal Ida Hospital, Kawasaki, Japan.

ORCID-Profile: Masami Tanaka, Shu Meguro

Förderung

  • Kowa Company

Zitieren

APA

Shigeta, A., Tanaka, M., Meguro, S., Morimoto, J., Imai, T., Yamauchi, A., Kanazawa, Y., Kawai, T., Azuma, K., Yamada, S., Endo, S., Itoh, H., & Hayashi, K. (2025). Effect of administration and withdrawal of the sodium‐glucose cotransporter 2 inhibitor, tofogliflozin, on renal protection in individuals with type 2 diabetes mellitus and diabetic nephropathy: A multicenter, single‐arm study ( RESTORE ‐nephropathy study). Journal of Diabetes Investigation. https://doi.org/10.1111/jdi.70018

Vancouver

Shigeta A, Tanaka M, Meguro S, Morimoto J, Imai T, Yamauchi A, et al. Effect of administration and withdrawal of the sodium‐glucose cotransporter 2 inhibitor, tofogliflozin, on renal protection in individuals with type 2 diabetes mellitus and diabetic nephropathy: A multicenter, single‐arm study ( RESTORE ‐nephropathy study). Journal of Diabetes Investigation. 2025. doi:10.1111/jdi.70018

BibTeX
@article{Shigeta2025,
  author = {Shigeta, Ayako and Tanaka, Masami and Meguro, Shu and Morimoto, Jiro and Imai, Takatoshi and Yamauchi, Akira and Kanazawa, Yasuhiko and Kawai, Toshihide and Azuma, Koichiro and Yamada, Satoru and Endo, Sho and Itoh, Hiroshi and Hayashi, Kaori},
  title = {Effect of administration and withdrawal of the sodium‐glucose cotransporter 2 inhibitor, tofogliflozin, on renal protection in individuals with type 2 diabetes mellitus and diabetic nephropathy: A multicenter, single‐arm study ( RESTORE ‐nephropathy study)},
  journal = {Journal of Diabetes Investigation},
  year = {2025},
  doi = {10.1111/jdi.70018}
}
Kostenlos starten →